An Israeli startup that uses artificial intelligence to diagnose cancer has unveiled a new solution that will help pathologists detect the specific treatments that will benefit breast cancer patients most.
Ibex Medical Analytics’ Galen Breast HER2 platform can accurately determine the expression in cancer slides of the protein HER2, which is responsible for the proliferation of breast cancer cells.
The platform uses AI to analyze the slides, identify the tumor cells and rapidly calculate the HER2 score of the tissue. The results are highlighted for the pathologist, who can review them and make a final decision as to what cancer treatment is best for each patient.
Traditionally, pathologists evaluate HER2 in tumor samples visually, which may result in varied interpretations. The Galen Breast HER2 scoring system quantifies the sample’s expression of the protein into four standard categories to help the pathologist make a more accurate decision.
The technology was developed and validated by Ibex in collaboration with AstraZeneca, the British-Swedish multinational biotechnology company, and Daiichi Sankyo, a Japanese pharma company.
“We are committed to providing pathologists with the most comprehensive AI platform as they implement digital pathology,” said Issar Yazbin, VP Product Management at Ibex Medical Analytics.
“In addition to HER2, we are now able to support full review of breast biopsies and excisions, distinguish between multiple types of invasive and non-invasive cancer, detect more than 50 malignant and non-malignant morphological features, and provide the underlying technology for automated quantification of additional prognostic and predictive breast biomarkers such as Ki-67, ER and PR.”